Since the first lung transplantation in 1990 at the Nazih Zuhdi Transplant Institute, more than 250 patients have successfully received lung transplants at INTEGRIS Baptist Medical Center in Oklahoma City.
Since the first lung transplantation in 1990 at the Nazih Zuhdi Transplant Institute, more than 250 patients have successfully received lung transplants at INTEGRIS Baptist Medical Center in Oklahoma City.
We now offer online organ transplant referral forms.
The lung transplant center at the INTEGRIS Nazih Zuhdi Transplant Institute in Oklahoma City is thriving. We have one of the largest and most experienced transplant teams in the US and receive referrals for patients seeking lung transplants from physicians across the country. Our dedicated transplant intensive care unit has a full-time transplant/critical care specialist who manages the patients 24 hours a day.
See our full lung transplant referral criteria list.
We offer potential lung transplant patients:
As a part of your informed consent, we are notifying you that all CMS outcome requirements are being met by our program. We are also informing you of our current post-transplant survival rates which we have summarized in the paragraph and table below.
The Scientific Registry of Transplant Recipients (SRTR) is a national database related to all solid organ transplants. Patient survival rates are calculated for 1 year and 3 years post-transplant. The adult lung transplant survival rates published by SRTR in January 2020 are listed in the table below. This information is updated every January and July by the SRTR. Information specific to each transplant center is available at www.srtr.org. If you do not have access to the Internet and wish to review any or all of the data available from SRTR, our transplant coordinators will be happy to provide you with a copy at your request.
1 Year Survival |
NZTI |
NZTI Expected |
National |
Patient |
89.68% |
88.63% | 89.32% |
Graft |
89.86% | 87.43% |
88.76% |
We have outstanding outcomes, click here for more information.